"Premature accelerated atherosclerosis is one of the leading causes of death and disability in lupus," said Nilamadhab Mishra, M.D., a rheumatologist at Wake Forest University Baptist Medical Center. Using a drug called Trichostatin A (TSA) "may prevent or decrease premature atherosclerosis in lupus."
Mishra presented his findings today (Nov. 16) at the American College of Rheumatology meeting in San Diego.
The findings represent a merger of two lines of Mishra's animal research using TSA one showing that the drug reduced lupus symptoms, especially inflammation of the kidneys and enlarged spleens, and the other showing that TSA was effective against atherosclerosis.
Mishra was joined in the atherosclerosis research by several leading scientists in the Medical School's long-standing atherosclerosis research program.
Their research uses a mouse that was created to be prone to atherosclerosis when fed a diet high in cholesterol and with 10 percent of calories from palm oil, one of the more dangerous dietary vegetable fats since it is high in saturated fat.
Among the atherosclerosis researchers were John S. Parks, Ph.D., professor of comparative medicine, and Richard St. Clair, Ph.D., professor of pathology and head of the Section on Comparative Medicine.
For 12 weeks, the researchers fed a high-fat, high-cholesterol diet to two groups of the atherosclerosis-prone mice. One group got injections of TSA from the time they went on the diet, while the other group got no TSA. The TSA-treated group had markedly less atherosclerosis in key arteries, such as the aorta the body's main blood vessel and what plaque there was contained less cholesterol.
Scientists increasing
'"/>
Contact: Robert Conn
rconn@wfubmc.edu
336-716-4587
Wake Forest University Baptist Medical Center
16-Nov-2005